摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8R,14S)-2,3,10,11-tetramethoxy-8-methyl-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine | 57030-06-5

中文名称
——
中文别名
——
英文名称
(8R,14S)-2,3,10,11-tetramethoxy-8-methyl-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine
英文别名
DC037005;O-Methylcorytenchirin;Coralydin;Corytenchirin-O-methylether;(8R,13aS)-2,3,10,11-tetramethoxy-8-methyl-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline
(8R,14S)-2,3,10,11-tetramethoxy-8-methyl-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine化学式
CAS
57030-06-5
化学式
C22H27NO4
mdl
——
分子量
369.461
InChiKey
ZAODQVCWAXRSRG-ACJLOTCBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    476.0±45.0 °C(Predicted)
  • 密度:
    1.21±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    40.2
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Bischler−Napieralski Cyclization−<i>N</i>/<i>C</i>-Alkylation Sequences for the Construction of Isoquinoline Alkaloids. Synthesis of Protoberberines and Benzo[<i>c</i>]phenanthridines <i>via</i> C-2‘-Functionalized 3-Arylisoquinolines<sup>1</sup>
    作者:Nuria Sotomayor、Esther Domínguez、Esther Lete
    DOI:10.1021/jo960007s
    日期:1996.1.1
    regioselectively yielded 2,3-disubstituted 13,14-dihydroprotoberberinium salts 20, a scarcely studied oxidation state in this class of alkaloids. Subsequent reduction of the iminium bond gave the known coralydine (21a) and O-methylcorytenchirine (21b) and their 8-phenyl analogue 21c. The one-pot preparation of these dihydroprotoberberinium salts 20 is shown to proceed with cleavage of the silyl ether and immediate
    据报道,有效合成路线为原小ber碱和苯并[c]菲啶类的异喹啉生物碱。关键的转化来自于C-2'-官能化的N-(1,2-二芳基乙基)酰胺或烯酰胺经过3-芳基异喹啉衍生物的分子内环化作用。因此,在Bischler-Napieralski反应条件(PCl(5),腈作为溶剂,室温)下,N-(1,2-二芳基乙基)酰胺12区域选择性地生成2,3-二取代的13,14-dihydroprotoberberinium盐20这类生物碱中的氧化态。随后亚胺键的还原得到已知的珊瑚素(21a)和O-甲基二十碳五烯碱(21b)及其8-苯基类似物21c。已显示一锅制备这些二氢pro小ber碱盐20时先裂解甲硅烷基醚并立即卤化所得羟基,然后将所得N-(1,2-二芳基乙基)酰胺18环化为3, 4-二氢异喹啉衍生物19和随后的亚胺的分子内原位N-烷基化。还介绍了容易获得的平面8,9-二烷氧基化苯并[c]菲啶鎓盐。在氯化钛(IV
  • HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    公开号:US20140088130A1
    公开(公告)日:2014-03-27
    The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
    本发明涉及一种由通式(I)表示的新型六氢二苯并[a,g]喹啉化合物及其衍生物、对映体、非对映体异构体、混合物以及其药学上可接受的盐。本发明还涉及一种制备该化合物的方法,该化合物对神经系统疾病具有良好的预防和治疗效果,特别是与多巴胺受体和5-羟色胺受体相关的疾病。生物活性实验证明,该化合物有望被开发成一种新型和有效的化学实体,用于治疗与多巴胺受体和5-羟色胺受体相关的疾病,特别是精神分裂症、帕金森病、药物成瘾、偏头痛等疾病。
  • PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS
    申请人:Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    公开号:EP2992883A1
    公开(公告)日:2016-03-09
    Use of hexahydro-dibenzo[a,g]quinolizine compounds as shown in formula(I) in preparing a medicine for treating and/or preventing benign prostate hyperplasia diseases.
    如式(I)所示六氢-二苯并[a,g]喹嗪化合物在制备治疗和/或预防良性前列腺增生疾病药物中的用途。
  • [EN] HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] COMPOSÉ D'HEXAHYDRODIBENZO[A,G]QUINOLIZINE, SON PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
    申请人:SHANGHAI INST MATERIA MEDICA
    公开号:WO2012163179A1
    公开(公告)日:2012-12-06
    发明涉及一种具有通式(I)所示的新颖的六氢二苯并[a,g]喹嗪类化合物及其衍生物,其对映异构体、非对映异构体、外消旋体及其混合物,及其药学上可接受的盐。本发明还涉及该类化合物的制备方法,另外该类化合物对神经系统疾病,特别是与多巴胺受体和五羟色胺受体相关的疾病有较好的防治作用。生物学活性实验表明,该类化合物有望开发成为一类治疗与多巴胺受体及五羟色胺受体相关的疾病特别是精神分裂症、帕金森氏症、药物成瘾性、偏头痛等疾病的强效的新化学实体。
  • An Approach to the Synthesis of Tetrahydroisoquinoline Alkaloids by Alkene Hydroamination: Synthesis of Coralydine
    作者:Cyrille Kouklovsky、Annie Pouilhès、Jean-Pierre Baltaze
    DOI:10.1055/s-0033-1339375
    日期:——
    The protoberberine alkaloid coralydine was synthesized in a short sequence by a strategy including an intramolecular alkene hydroamination as the key step, followed by a Pictet-Spengler cyclization.
查看更多